HRP20230384T1 - Postupak za razvoj monoklonskih antitijela - Google Patents
Postupak za razvoj monoklonskih antitijela Download PDFInfo
- Publication number
- HRP20230384T1 HRP20230384T1 HRP20230384TT HRP20230384T HRP20230384T1 HR P20230384 T1 HRP20230384 T1 HR P20230384T1 HR P20230384T T HRP20230384T T HR P20230384TT HR P20230384 T HRP20230384 T HR P20230384T HR P20230384 T1 HRP20230384 T1 HR P20230384T1
- Authority
- HR
- Croatia
- Prior art keywords
- cells
- heavy
- light
- monoclonal antibodies
- antibodies
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 7
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 210000004989 spleen cell Anatomy 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 239000013613 expression plasmid Substances 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 210000004976 peripheral blood cell Anatomy 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Claims (5)
1. In vitro postupak za razvoj monoklonskih antitijela, pri čemu navedeni postupak sadrži korake:
(a) obogaćivanja izvornog materijala hvatanjem specifičnih stanica na čijoj su površini antitijela izložena na plastičnim površinama napunjenim antigenom pri čemu to hvatanje uključuje podloge za hvatanje koje sadrži 0,5% tež/ob BSA i 0,1% tež/ob NaN3
(b) omplifikacije cDNK kodiranja za teški (VH) i laki (VL) lanac promjenljive domene;
(c) konstrukcija kombinatorne teške (VH) i lake (VL) knjižnice DNK formata plazmida ekspresije sisavaca
(d) identifikacije propisnih za antigen specifičnih kombinacija vezivanja teških (VH) - lakih (VL) lanaca promjenljive domene nakon eksprimiranja antitijela u stanicama sisavaca.
2. Postupak sukladno patentnom zahtjevu 1, pri čemu se stanice izvora izabiru od skupine koju čine stanice slezene iz sirovog homogenata slezene, koštane srži i stanica periferne krvi iz imunizirane životinje.
3. Postupak sukladno patentnom zahtjevu 1 ili 2, pri čemu koraku a) prethodi korak predapsorpcije gdje su stanice izvora kratko pre-adsorbirane s prekomjernom količinom antigena koji nisu ciljani.
4. Postupak za proizvodnju monoklonskih antitijela, pri čemu se antitijela razvijaju sukladno bilo kojem od prethodnih patentnih zahtjeva, i stanice sisavaca identificirane u koraku d) dalje kultiviraju u velikoj količini za proizvodnju antitijela.
5. Postupak sukladno patentnom zahtjevu 3, pri čemu su ta antitijela bez antigena koji nisu ciljani.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562234927P | 2015-09-30 | 2015-09-30 | |
| EP16781314.6A EP3356398B1 (en) | 2015-09-30 | 2016-09-30 | A method for development of monoclonal antibodies |
| PCT/EP2016/073524 WO2017055617A2 (en) | 2015-09-30 | 2016-09-30 | A method for development of monoclonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230384T1 true HRP20230384T1 (hr) | 2023-06-23 |
Family
ID=57133140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230384TT HRP20230384T1 (hr) | 2015-09-30 | 2016-09-30 | Postupak za razvoj monoklonskih antitijela |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10995134B2 (hr) |
| EP (1) | EP3356398B1 (hr) |
| CA (1) | CA2999158A1 (hr) |
| DK (1) | DK3356398T3 (hr) |
| ES (1) | ES2942657T3 (hr) |
| FI (1) | FI3356398T3 (hr) |
| HR (1) | HRP20230384T1 (hr) |
| LT (1) | LT3356398T (hr) |
| PL (1) | PL3356398T3 (hr) |
| PT (1) | PT3356398T (hr) |
| SI (1) | SI3356398T1 (hr) |
| WO (1) | WO2017055617A2 (hr) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0312481D0 (en) * | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
-
2016
- 2016-09-30 EP EP16781314.6A patent/EP3356398B1/en active Active
- 2016-09-30 SI SI201631691T patent/SI3356398T1/sl unknown
- 2016-09-30 US US15/764,990 patent/US10995134B2/en active Active
- 2016-09-30 HR HRP20230384TT patent/HRP20230384T1/hr unknown
- 2016-09-30 CA CA2999158A patent/CA2999158A1/en active Pending
- 2016-09-30 ES ES16781314T patent/ES2942657T3/es active Active
- 2016-09-30 LT LTEPPCT/EP2016/073524T patent/LT3356398T/lt unknown
- 2016-09-30 PT PT167813146T patent/PT3356398T/pt unknown
- 2016-09-30 WO PCT/EP2016/073524 patent/WO2017055617A2/en active Application Filing
- 2016-09-30 PL PL16781314.6T patent/PL3356398T3/pl unknown
- 2016-09-30 FI FIEP16781314.6T patent/FI3356398T3/fi active
- 2016-09-30 DK DK16781314.6T patent/DK3356398T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3356398A2 (en) | 2018-08-08 |
| WO2017055617A3 (en) | 2017-05-11 |
| CA2999158A1 (en) | 2017-04-06 |
| LT3356398T (lt) | 2023-06-12 |
| EP3356398B1 (en) | 2023-01-25 |
| US20180273611A1 (en) | 2018-09-27 |
| FI3356398T3 (fi) | 2023-05-03 |
| SI3356398T1 (sl) | 2023-09-29 |
| PL3356398T3 (pl) | 2023-10-02 |
| WO2017055617A2 (en) | 2017-04-06 |
| DK3356398T3 (da) | 2023-05-01 |
| PT3356398T (pt) | 2023-04-28 |
| US10995134B2 (en) | 2021-05-04 |
| ES2942657T3 (es) | 2023-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Implantation initiation of self-assembled embryo-like structures generated using three types of mouse blastocyst-derived stem cells | |
| HRP20191704T1 (hr) | Multispecifična protutijela | |
| BR112013027420A2 (pt) | "uso de camundongos geneticamente modificados na preparação de um anticorpo e método para produzir anticorpos". | |
| HRP20191409T1 (hr) | Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula | |
| ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
| PH12018500295A1 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
| EA201691925A1 (ru) | Биспецифические антитела, которые связываются с cd38 и cd3 | |
| MX2015012540A (es) | Ratón de cadena ligera común. | |
| MX2019010583A (es) | Anticuerpos contra ligando 1 de muerte programada. | |
| CU20180024A7 (es) | Moléculas de unión a linfopoyetina estromal tímica (tslp), composiciones farmacéuticas que las contienen y método de producción de las mismas | |
| MX2011010027A (es) | Anticuerpos solubles "solo de cadena pesada". | |
| SG10201810825YA (en) | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same | |
| IN2014DN08163A (hr) | ||
| TR201901668T4 (tr) | Sınırlı bir immünoglobulin hafif zincir repertuvarını eksprese eden fareler. | |
| BR112012026766A2 (pt) | métodos in vitro para gerar uma proteína heterodimérica, para a seleção de um anticorpo biespecífico e para inibir o crescimento, vetor de expressão, célula hospedeira, proteína heterodimérica, composição farmacêutica. | |
| PH12020500160A1 (en) | Reagents for expanding cells expressing recombinant receptors | |
| JP6182631B2 (ja) | 抗原特異性を有するハイブリドーマ細胞のスクリーニング方法 | |
| UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
| AR118763A1 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| BR112021016955A2 (pt) | Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico | |
| HRP20230384T1 (hr) | Postupak za razvoj monoklonskih antitijela | |
| BR112022003170A2 (pt) | Desenvolvimento de uma plataforma de hibridoma eficiente para descoberta de anticorpo terapêutico | |
| AR113343A1 (es) | ANTICUERPO MONOCLONAL ANTI-IL-5Ra | |
| UY37915A (es) | Anticuerpos específicos para cd47 y pd-l1 | |
| WO2017062966A8 (en) | Antibodies specific for 4,6-diamino-5-(formylamino) pyrimidine and uses thereof |